Vitasang

Vitasang is a life sciences company dedicated to transforming blood management and transfusion medicine through its proprietary blood rejuvenation technologies. The company's lead product, Rejuvesol, is an FDA-approved solution used for the extracorporeal rejuvenation of red blood cells, effectively restoring 2,3-diphosphoglycerate (2,3-DPG) and adenosine triphosphate (ATP) levels that typically decline during storage. Vitasang is also advancing the development of a point-of-care rejuvenation device designed for bedside use in hospitals and blood banks to ensure patients receive high-quality, "fresh" blood. Beyond its core focus on hematology, the company is investigating applications for its technology in oncology to improve outcomes for hypoxic tumors and is active in the longevity research space, including funding clinical trials for rapamycin.